The multi-year collaboration will incorporate NextCure's proprietary FIND-IO platform, a technology designed to identify novel cell-surface molecular interactions that drive functional immune responses in the tumor microenvironment and other disease sites.
The International Society for Pharmaceutical Engineering (ISPE) named Shire as the ISPE 2018 Facility of the Year Awards Overall Winner for a facility integration project in Los Angeles, CA.
Pharmatech Associates International Contracting and Services is a new company headquartered in Doha, Qatar, that will provide product development, facility design, and construction for high quality pharmaceutical and biotech products at low cost.
The expansion adds new capabilities and enhances existing service offerings for both oral and parenteral dosage forms.
The company has rolled out the first batch of TRACON Pharmaceutical’s lead product candidate from its Singapore-based single-use bioreactor.
Researchers evaluated the chemical stability of two different naloxone products administered to prevent opioid overdose deaths and found the products to have a significantly extended shelf life than previously known.
Bioprocessing and manufacturing events bioLIVE and BioProduction Congress will take place as one event adjacent to CPhI Worldwide in Frankfurt, Germany, on November 5–7, 2019.
Irish manufacturer of generic medicines for both human and animal health, Chanelle Pharma, has been named as Pharma Industry Company of the Year 2018.
A new report from the Fraser of Allander Institute (FAI) at the University of Strathclyde has shown that the Scottish pharmaceutical industry is 'booming'.
A London-based pharmaceutical company has been charged with offences relating to the nature and quality of medicinal product used for parenteral nutrition in babies.
Copley Scientific-a manufacturer and provider of test instrumentations for pharmaceutical dosage forms-has officially opened its newly expanded headquarters in Colwick, United Kingdom.
Cytek Biosciences’ Northern Lights series of advanced flow cytometry systems brings reagent and application flexibility to more labs while enhancing performance.
GiroNEX’s precision powder dispensing technology is expected to enable a new range of automated “dispense and weigh” systems for use in R&D and other lab-based applications.
Thermo Fisher Scientific’s Savant SpeedVac systems now offer preset and custom-made programs for improved application flexibility.
The company received FDA approval for Hyrimoz (adalimumab-adaz), its biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).
The latest Manufacturing Barometer report, published by SWMAS, indicates concern over Brexit by UK manufacturers and an anticipation of lower business growth over the next six months.
Thermo Fisher Scientific has entered into a collaboration with Symphogen to deliver validated, platform workflows for simplified characterisation and quality monitoring of complex therapeutic proteins.
This new partnership provides access to Distributed Bio’s antibody discovery platforms.
The company has broken ground on the construction of a new laboratory space.
he acquisition expands the company’s formulation and analytical R&D services.
The company introduced a new approach to chemical imaging that provides enhanced clarity.
New data highlights ability of the SQZ cell therapy platform to preserve cellular functions.
A project funded by BioProNET will investigate optimization for bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields.
A statement from FDA Commissioner Scott Gottlieb and Deputy Commissioner Anna Abram detailed FDA’s new plan to advance plant and animal biotechnology innovation.
The company has expanded its operations in the United States with the opening of a new 45,000-ft2, early-phase formulation and manufacturing facility located in Garnet Valley, PA.
The acquisition will allow Lonza to further develop technology for scalable autologous cell-therapy manufacturing.
The companies announced the European launch of Imraldi (adalimumab), a biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).
Mylan announced the launch of its biosimilar to AbbVie’s Humira across major European markets.
The latest CPhI Worldwide survey results have revealed a promising outlook for the global pharma economies.
Idifarma, a contract development and manufacturing organisation (CDMO), based in Spain, has announced the commencement of the seventh project with Palobiofarma-a Spanish biotechnology company.
